Member Info for Kjn2

Agree Finlay, break price around 140-145p.

Takes long time. Seems outside in Tosca can’t finance themselves? And if Mediclinic don’t want to roll over their stake, deal could be instantly dead and stock crashes.

Some of the large medtech / wound care companies, especially in the US, have a history of tuck-in / small M&A.

Now that HB Fuller taking a look at the company, all their internal M&A departments could assess a deal now. 285p won’t be the final offer imo.

Now that the first strategic potential buyer showed his cards I think J&J, S&N, Stryker and the many other large peers could take a look at AMS. They could all easily pay 320-330p and distribute the AMS products across their distribution network. I think more to come, hopefully soon.

Strong spread at 13% now. That’s decent by now.

Could fall apart, not sure that Tosca could have all the funding in place? And if Mediclinic not on board, deal can’t be done.

If no deal back to 145p.

Danger mouse: Kendal (known as clown on this forum) has been spamming many stocks and users here. He doesn’t know any basics, just block/report and move on. Not worth your time this clown.

Kenal you clown, stop spamming the forum with your garbage. Most uninformed clown.

Do everyone a favour and get lost.

I would still argue that the Board need to run a sale auction now.

- share price hasn’t seen 300p since 2022, that’s partially the Board’s / management’s work. The market’s view won’t change quickly. The share hasn’t performed in a very long time.

- several suitors have been interested. From PE to now strategic party, plenty of interest. Instead of having this odd continuous PUSU ping pong they should run an auction imo.

- For many wound care companies AMS is an add-on deal. They can use their distribution channels to push AMS products.

- no buyback program atm, no one knows why. Again, the company has not been very good at capital allocation in my view.

Time that shareholders get awarded.

Has anyone spoken to the company? Why hadn’t the Board run an auction yet? Share price been in nomansland for years, now that there is strategic interest they should sell the company to the highest bidder. Time that shareholders profit after years of stagnation. Board needs to deliver imo.

Indeed, I would argue AMS is a great tuck-in takeover for the likes of Stryker, J&J, S&N etc

I can also see an activist getting involved here. As in I’m surprised the Board hasn’t launched a strategic review / auction. Holding out for the last or additional 25-30p for too many years can hinder shareholders finally realize some value. The shares haven’t moved in 3-4 years which for the industry is remarkable.

Today is ex-dividend day for everyone wondering why the share is down.

Yeah that analysis is a bit of a joke I’m afraid.

If standalone value is supposed to be 290, takeout value can’t be 320 needless to say. And AMS barely has any net leverage, so can’t be the moving factor whatsoever.

I’d stick to proper sell side research for now and discount a bit higher. Imo 300 seems to be the hurdle, I think the Board has to put forward an offer that high.

I think it would help all shareholders if the Board ran a proper strategic review. Otherwise, it doesn’t help the owners of every other month a non binding bid gets shut down / the bid ask is too wide. I’m surprised they haven’t done it yet, plenty of buyer interest out there clearly.

The stock hasn’t done anything in years. Time for the Board to step it up imo.

Stock down 2.5% so far today

Time that an activist pushes the AMS Board for a sale? All these approaches and no good outcome for shareholders.

The letter from the HB Fuller holder is a complete joke. They hold 2% or so and want that they sell HB Fuller. One of the worst “activist letters” I have read.

Anyway, HB Fuller’s interest should put AMS on the market for strategic buyers like Medtronic, Johnson and Johnson, Baxter, Stryker and B Braun as well as Smith and Nephew.

Plenty of potential buyers.

The release is as vague as no other. “Minded”, roll over into private entity, no binding offer, look at the TalkTalk precedent. That is unusual for 2.4 releases and massive downside from here. But clown, you wouldn’t know. Belly laugh to 150p.

Clown: Large blocks sold this week. Tosca imo can’t find the deal themselves. And if Mediclinic don’t want to roll over into a private entity the share price could drop all the way back to 150p.

Selling economics is selling economics.

He is almost out.

I’m bearish here. Saw the TalkTalk precedent.

He sold another 3 million shares.